Jan. 2004 : two new founding managers, Thierry Bourbié and Jean-Pierre Rogala, joined the Company
2005-2008 : iXCore buys into the capital of Pharmaleads investing €4 million over 4 years
Dec. 2005 : signature of its first non-exclusive license for the quantification of botulinum toxin (for application in the medical and cosmetic domain)
Aug 2006 : the network of surveillance laboratories over French territory is equipped with the EzyBot® field case
Oct. 2008 : signature of an exclusive license for the its lead pain molecule with the Swiss Company Debiopharm
2008-2012 : development of Pharmaleads’ pipeline of drug molecules for pain alleviation
Ap. 2012 : Nature Reviews Drug Discovery (NRDD) published an article by Pharmaleads top scientists on DENKIS
